Not Yet Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm
NCT07388277
CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
A Phase I/II Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Sponsor: Bristol-Myers Squibb
Interventions
CC-97540 Lymphodepletion Chemotherapy
Updated 1 time since 2026 Last updated: Feb 4, 2026 Started: Jul 9, 2026 Primary completion: Dec 31, 2028 Completion: Dec 31, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE1/PHASE2 trial investigates Antineutrophil Cytoplasmic Antibody-associated Vasculitis and is currently actively recruiting participants. Bristol-Myers Squibb leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE1/PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Bristol-Myers Squibb
- Marcela V. Maus, M.D.,Ph.D.
Data source: Massachusetts General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .